Clinical trial
Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of…
NCT00228553 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00228553 |
|---|---|
| Title | Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness |
| Official title | A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With… |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder |
| Intervention type | Drug |
| Interventions | Armodafinil 100 to 250 mg/day |
| Enrollment | 743 |
| Start date | May 1, 2004 |
| Completion | Jul 1, 2006 |
| First posted | Sep 29, 2005 |
| Last update posted | Jul 19, 2013 |
| Countries | Australia, Canada, France, Germany, Puerto Rico, Russia, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: